| 1 | Osteoporosis in adult Sri Lankan inflammatory bowel disease patients显示文摘AIM:To determine if inflammatory bowel disease(IBD) is a risk factor for osteoporosis in adult Sr Lankans.METHODS:We identified eligible subjects from among consecutive patients diagnosed with IBD who attended our outpatient clinic.We included only patients aged between 20 and 70 years.Patients who were pregnant, had significant comorbidity, or were on calcium supplements or treatment for osteoporosis within the past 6 mo, were excluded.Healthy, ageand sex-matched controls were also recruited, ina control to patient ratio of 3:1.Both groups were screened for osteoporosis using peripheral dual energy X-ray absorptiometry scanning.RESULTS:The study population consisted of 111 IBD patients(male:female = 43:68;mean age 42.5 years) and 333 controls(male:female = 129:204;mean age 43.8 years).The occurrence of osteoporosis among IBD patients(13.5%) was significantly higher than among controls(4.5%)(P = 0.001).The frequency of osteoporosis was not significantly different between ulcerative colitis(14.45%) and Crohn's disease(10.7%).However, on multivariate analysis, only age(P = 0.001), menopause(P = 0.024) and use of systemic steroids(P < 0.001) were found to be associated independently with the occurrence of osteoporosis, while IBD, severity of disease, number of relapses, duration of illness or treatment other than systemic steroids were not.CONCLUSION:IBD does not appear to be an independent risk factor for the occurrence of osteoporosis in this population.However, the use of systemic steroids was a risk factor. | Arjuna Priyadarsin de Silva Aranjan Lionel Karunanayake Thalahitiya Gamaralalage Iruka Dissanayaka Anuradha Supun Dassanayake Hewa Kattadi Kankanamgae Tilak Duminda Arunasalam Pathmeswaran Ananda Rajitha Wickramasinghe Hithanadura Janaka de Silva | 2009 | World Journal of Gastroenterology2009，15，28： | 0 |
| 2 | Bones and Crohn’s:No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D显示文摘AIM: To compare the effect of calcium and cholecalciferol alone and along with additional sodium fluoride or ibandronate on bone mineral density (BMD) and fractures in patients with Crohn's disease (CD). METHODS: Patients (n =148) with reduced BMD (T-score < -1) were randomized to receive cholecalciferol (1000 IU) and calcium citrate (800 mg) daily alone(group A, n = 32) or along with additional sodium fluoride (25 mg bid) (group B, n = 62) or additional ibandronate (1 mg iv/3-monthly) (group C, n = 54). Dual energy X-ray absorptiometry of the lumbar spine (L1-L4) and proximal right femur and X-rays of the spine were performed at baseline and after 1.0, 2.25 and 3.5 years. Fracture-assessment included visual reading of X-rays and quantitative morphometry of vertebral bodies (T4-L4).RESULTS: One hundred and twenty three (83.1%) patients completed the first year for intention-to-treat (ITT) analysis. Ninety two (62.2%) patients completed the second year and 71 (47.8%) the third year available for per-protocol (PP) analysis. With a significant increase in T-score of the lumbar spine by +0.28 ± 0.35 [95% conf idence interval (CI): 0.162-0.460, P < 0.01], +0.33 ± 0.49 (95% CI: 0.109-0.558, P < 0.01), +0.43 ± 0.47 (95% CI: 0.147-0.708, P < 0.01) in group A, +0.22 ± 0.33 (95% CI: 0.125-0.321, P < 0.01); +0.47 ± 0.60 (95% CI: 0.262-0.676, P < 0.01), +0.51 ± 0.44 (95% CI: 0.338-0.682, P < 0.01) in group B and +0.22 ± 0.38 (95% CI: 0.111-0.329, P < 0.01), +0.36 ± 0.53 (95% CI: 0.147-0.578, P < 0.01), +0.41 ± 0.48 (95% CI: 0.238-0.576, P < 0.01) in group C, respectively, during the 1.0, 2.25 and 3.5 year periods (PP analysis), no treatment regimen was superior in any in- or between-group analyses. In the ITT analysis, similar results in all in- and between-group analyses with a significant in-group but non-significant between-group increase in T-score of the lumbar spine by 0.38 ± 0.46 (group A, P < 0.01), 0.37 ± 0.50 (group B, P < 0.01) and 0.35 ± 0.49 (group C, P < 0.01) was observed. Follow-up in ITT analysis was still 2.65 years. One vertebral fracture in the sodium fluoride group was detected. Study medication was safe and well tolerated. CONCLUSION: Additional sodium fluoride or ibandronate had no benefit over calcium and cholecalciferol alone in managing reduced BMD in CD. | Jochen Klaus Max Reinshagen Katharina Herdt Christoph Schrter Guido Adler Georg BT von Boyen Christian von Tirpitz | 2011 | World Journal of Gastroenterology2011，17，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员